Skip to main content
AAN.com
Articles
June 14, 2010

Familial cortical myoclonic tremor with epilepsy
The third locus (FCMTE3) maps to 5p

June 15, 2010 issue
74 (24) 2000-2003

Abstract

Background: Familial cortical myoclonic tremor with epilepsy (FCMTE) is defined by autosomal dominant adult-onset cortical myoclonus (CM) and seizures in 40% of patients. Two loci, 8q23.3-q24.11 (FAME1/FCMTE1) and 2p11.1-q12.2 (FAME2/FCMTE2), were previously reported without an identified gene. Unlinked families argue for a third mutated gene.
Methods: A genome-wide scan was performed in a large FCMTE family using Linkage-12 microarrays (Illumina). Refinement of the locus on 5p was performed by genotyping 13 polymorphic microsatellite markers in the 45 available family members.
Results: This large French FCMTE family included 16 affected relatives. The first symptoms were CM in 5 patients (31.2%), seizures in 5 patients (31.2%), and both at the same time in 6 patients (37.5%). A total of 12.5% (2/16) had only CM without seizures. The genome-wide scan identified a single region on 5p15.31-p15, with a multipoint lod score of 3.66. Further genotyping of all family members confirmed that the region spans 9.31 Mb between D5S580 and D5S2096, 2-point lod scores reaching 6.3 at θ = 0 for D5S486. Sequencing of the SEMA5A and CTNND2 genes failed to detect mutations.
Conclusions: We report the clinical and genetic characteristics of a large familial cortical myoclonic tremor with epilepsy family. The third gene maps to 5p15.31-p15. Identification of the mutated gene is ongoing.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (figure_e-1.tif)
File (figure_e-2.tif)
File (figure_legends.doc)

REFERENCES

1.
van Rootselaar AF, van Schaik IN, van den Maagdenberg AM, et al. Familial cortical myoclonic tremor with epilepsy: a single syndromic classification for a group of pedigrees bearing common features. Mov Disord 2005;20:665–673.
2.
Guerrini R, Bonanni P, Patrignani A, et al. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with complex partial and generalized seizures: a newly recognized epilepsy syndrome with linkage to chromosome 2p11.1-q12.2. Brain 2001;124:2459–2475.
3.
Elia M, Musumeci SA, Ferri R, et al. Familial cortical tremor, epilepsy, and mental retardation: a distinct clinical entity?. Arch Neurol 1998;55:1569–1573.
4.
Carr JA, van der Walt PE, Nakayama J, et al. FAME 3: a novel form of progressive myoclonus and epilepsy. Neurology 2007;68:1382–1389.
5.
Mikami M, Yasuda T, Terao A, et al. Localization of a gene for benign adult familial myoclonic epilepsy to chromosome 8q23.3-q24.1. Am J Human Genet 1999;65:745–751.
6.
Labauge P, Amer LO, Simonetta-Moreau M, et al. Absence of linkage to 8q24 in a European family with familial adult myoclonic epilepsy (FAME). Neurology 2002;58:941–944.
7.
Saint-Martin C, Bouteiller D, Stevanin G, et al. Refinement of the 2p11.1-q12.2 locus responsible for cortical tremor associated with epilepsy and exclusion of candidate genes. Neurogenetics 2008;9:69–71.
8.
Bourdain F, Apartis E, Trocello JM, et al. Clinical analysis in familial cortical myoclonic tremor allows differential diagnosis with essential tremor. Mov Disord 2006;21:599–608.
9.
Magnin E, Vidailhet M, Depienne C, et al. Familial cortical myoclonic tremor with epilepsy (FCMTE): clinical characteristics and exclusion of linkages to 8q and 2p in a large French family. Rev Neurol 2009;10:812–820.
10.
van Rootselaar AF, van der Salm SM, Bour LJ, et al. Decreased cortical inhibition and yet cerebellar pathology in ‘familial cortical myoclonic tremor with epilepsy.’ Mov Disord 2007;22:2378–2385.

Information & Authors

Information

Published In

Neurology®
Volume 74Number 24June 15, 2010
Pages: 2000-2003
PubMed: 20548044

Publication History

Published online: June 14, 2010
Published in issue: June 15, 2010

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

C. Depienne, PhD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
E. Magnin, MD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
D. Bouteiller, MS
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
G. Stevanin, PhD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
C. Saint-Martin, PhD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
M. Vidailhet, MD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
E. Apartis, MD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
E. Hirsch
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
E. LeGuern, MD, PhD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
P. Labauge, MD, PhD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.
L. Rumbach, MD, PhD
From INSERM (C.D., D.B., G.S., C.S.-M., M.V., E.L.), UMR_S975, Université Pierre et Marie Curie-Paris 6, CNRS 7225, Centre de Recherche–Institut du Cerveau et de la Moelle, Paris; AP-HP (C.D., M.V., E.L.), Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique et Cytogénétique, U.F. de Neurogénétique Moléculaire et Cellulaire, Paris; Department of Neurology (E.M., L.R.), CHU Jean Minjoz, Besançon; Department of Neurology (M.V.), CHU Salpêtrière Hospital, Paris; Department of Physiology (E.A.), Saint-Antoine Hospital, Paris; Department of Neurology (E.H.), CHU Strasbourg; and Department of Neurology (P.L.), CHU Nimes, France.

Notes

Address correspondence and reprint requests to Dr. Pierre Labauge, Department of Neurology, CHU de Nîmes, 30 209 Nîmes, Cedex, France [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Repeat Expansions with Small TTTCA Insertions in MARCHF6 Cause Familial Myoclonus without Epilepsy , Movement Disorders, (2025).https://doi.org/10.1002/mds.30192
    Crossref
  2. Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies, Movement Disorders, (2025).https://doi.org/10.1002/mds.30151
    Crossref
  3. Myoclonus, Movement Disorders Phenomenology, (339-418), (2024).https://doi.org/10.1007/978-3-031-52573-5_10
    Crossref
  4. Autism Spectrum Disorder- and/or Intellectual Disability-Associated Semaphorin-5A Exploits the Mechanism by Which Dock5 Signalosome Molecules Control Cell Shape, Current Issues in Molecular Biology, 46, 4, (3092-3107), (2024).https://doi.org/10.3390/cimb46040194
    Crossref
  5. RhoG-Binding Domain of Elmo1 Ameliorates Excessive Process Elongation Induced by Autism Spectrum Disorder-Associated Sema5A, Pathophysiology, 30, 4, (548-566), (2023).https://doi.org/10.3390/pathophysiology30040040
    Crossref
  6. Nine Hereditary Movement Disorders First Described in Asia: Their History and Evolution, Journal of Movement Disorders, 16, 3, (231-247), (2023).https://doi.org/10.14802/jmd.23065
    Crossref
  7. Familial Adult Myoclonus Epilepsy: A Non-Coding Repeat Expansion Disorder of Cerebellar–Thalamic–Cortical Loop, Cells, 12, 12, (1617), (2023).https://doi.org/10.3390/cells12121617
    Crossref
  8. Genetics of familial adult myoclonus epilepsy: From linkage studies to noncoding repeat expansions, Epilepsia, 64, S1, (2023).https://doi.org/10.1111/epi.17610
    Crossref
  9. Current treatment options for familial adult myoclonus epilepsy, Epilepsia, 64, S1, (2023).https://doi.org/10.1111/epi.17590
    Crossref
  10. History of familial adult myoclonus epilepsy/benign adult familial myoclonic epilepsy around the world, Epilepsia, 64, S1, (2023).https://doi.org/10.1111/epi.17519
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share